Your browser doesn't support javascript.
loading
Treatment of Chronic Heart Failure Patients with Qi-Yang Deficiency and Blood Stasis Resistance Syndrome by Xnmallong Injection: a Multi-center Randomized Control Study / 中国中西医结合杂志
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 796-800, 2015.
Artigo em Chinês | WPRIM | ID: wpr-237936
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of Xinmailong Injection (XI) in treatment of chronic heart failure (CHF) patients with qi-yang deficiency and blood stasis resistance syndrome (QY-DBSRS).</p><p><b>METHODS</b>Totally 238 CHF patients with QYDBSRS were assigned to the treatment group (118 cases) and the control group (120 cases) by randomized, double-blind, placebo parallel controlled method. Patients in the treatment group received routine therapy and XI (100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days), while those in the control group received routine therapy and XI mimetic agent (100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days). The heart function classification of New York Heart Association (NYHA), 6-min walking distance, left ventricular ejection fraction (LVEF), scores for Chinese medical symptoms were observed before and after treatment, and safety assessed.</p><p><b>RESULTS</b>Totally 235 patients actually entered full analysis set (FAS), including 120 cases in the control group and 115 cases in the treatment group. The total effective rate of heart function, 6-min walking distance and increased post-pre-treatment distance in the experimental group were superior to those of the control group with statistical difference (all P < 0.05). Compared with the control group, increased value of post-pre-treatment LVEF, the total effective rate of Chinese medical syndrome efficacy, scores for Chinese medical symptoms and decreased post-pre-treatment value of Chinese medical syndrome scores were obviously improved (all P < 0.05). There was no significant difference in the incidence of adverse events between the two groups (P > 0.05).</p><p><b>CONCLUSIONS</b>XI could improve the heart function of CHF patients, improve Chinese medical symptoms, elevate exercise tolerance, and improve LVEF. It had no obvious toxic and side effects.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Farmacologia / Síndrome / Medicamentos de Ervas Chinesas / Método Duplo-Cego / Doença Crônica / Deficiência da Energia Yang / Qi / Usos Terapêuticos / Tratamento Farmacológico / Insuficiência Cardíaca Tipo de estudo: Ensaio Clínico Controlado / Estudo diagnóstico Limite: Humanos Idioma: Chinês Revista: Chinese Journal of Integrated Traditional and Western Medicine Ano de publicação: 2015 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Farmacologia / Síndrome / Medicamentos de Ervas Chinesas / Método Duplo-Cego / Doença Crônica / Deficiência da Energia Yang / Qi / Usos Terapêuticos / Tratamento Farmacológico / Insuficiência Cardíaca Tipo de estudo: Ensaio Clínico Controlado / Estudo diagnóstico Limite: Humanos Idioma: Chinês Revista: Chinese Journal of Integrated Traditional and Western Medicine Ano de publicação: 2015 Tipo de documento: Artigo